Llovet, Josep M; Peña, Carol E A; Lathia, Chetan D; Shan, Michael; Meinhardt, Gerold; Bruix, Jordi (2012). Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clinical cancer research, 18(8), pp. 2290-300. Philadelphia, Pa.: American Association for Cancer Research 10.1158/1078-0432.CCR-11-2175
Full text not available from this repository. (Request a copy)Validated biomarkers of prognosis and response to drug have not been identified for patients with hepatocellular carcinoma (HCC). One of the objectives of the phase III, randomized, controlled Sorafenib HCC Assessment Randomized Protocol (SHARP) trial was to explore the ability of plasma biomarkers to predict prognosis and therapeutic efficacy.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Gastroenterology |
UniBE Contributor: |
Wiest, Reiner |
ISSN: |
1078-0432 |
Publisher: |
American Association for Cancer Research |
Language: |
English |
Submitter: |
Factscience Import |
Date Deposited: |
04 Oct 2013 14:40 |
Last Modified: |
05 Dec 2022 14:12 |
Publisher DOI: |
10.1158/1078-0432.CCR-11-2175 |
PubMed ID: |
22374331 |
Web of Science ID: |
000302907300020 |
URI: |
https://boris.unibe.ch/id/eprint/16180 (FactScience: 223768) |
Actions (login required)
 |
Edit item |